The NTCC? MOLT-16 cell line is a human cell line used as a model for T-cell acute lymphoblastic leukemia (T-ALL), a highly aggressive type of blood cancer. It was established from the peripheral blood of a 5-year-old girl who had a relapse of T-ALL.

Key Characteristics

• Origin: The cell line was derived in 1984 and is a sister cell line to MOLT-17.

• Cell Type: It is a T-lymphoblastoid cell line, meaning it is a type of white blood cell (T-cell) that has become cancerous and has immature characteristics (lymphoblast).

• Growth: The cells grow in suspension, which is typical for blood cancer cell lines.

• Genetic Profile:

  • It has a near-diploid karyotype, but with several complex chromosomal translocations.

  • A significant genetic feature is a translocation involving chromosomes 8 and 14, specifically t(8;14)(q24;q11). This translocation brings the MYC oncogene on chromosome 8 into close proximity with the T-cell receptor alpha chain (TCR-alpha) gene on chromosome 14, leading to the overexpression of the MYC oncogene, which is a known driver of cancer.

  • It expresses key T-cell markers such as CD2, CD3, CD5, CD7, and the T-cell receptor.

• Drug Sensitivity: The MOLT-16 cell line has been profiled for its sensitivity to various drugs, and this data is used in drug screening projects.

Research Applications

The MOLT-16 cell line is a valuable resource for oncology research, especially in the study of pediatric T-ALL. Its main applications include:

• Disease Modeling: It serves as a representative model for T-cell acute lymphoblastic leukemia, allowing researchers to study the disease's progression and unique biological properties.

• Genetic and Molecular Studies: The cell line is used to investigate the role of specific genetic mutations and translocations (like the t(8;14) translocation) in the development and maintenance of T-ALL.

• Drug Discovery and Screening: Due to its established genetic and drug-response profiles, it is a key tool for screening new therapeutic agents and understanding the mechanisms of drug resistance.

NTCC? MOLT-16 細(xì)胞系是一種人類細(xì)胞系，被用作**T 細(xì)胞急性淋巴細(xì)胞白血?。═-ALL）**的模型。T-ALL 是一種侵襲性極強的血液癌癥。該細(xì)胞系是從一名患有 T-ALL 復(fù)發(fā)的5歲女孩的外周血中建立的。

主要特點

• 來源: 該細(xì)胞系于1984年建立，是 MOLT-17 細(xì)胞系的姊妹系。

• 細(xì)胞類型: 它是 T 淋巴母細(xì)胞樣細(xì)胞系，意味著它是一種已癌變的白細(xì)胞（T 細(xì)胞），并具有未成熟的特征（淋巴母細(xì)胞）。

• 生長方式: 這些細(xì)胞在懸浮培養(yǎng)中生長，這是血癌細(xì)胞系的典型特征。

• 遺傳學(xué)特征:

  • 它具有近二倍體核型，但存在多個復(fù)雜的染色體易位。

  • 一個重要的遺傳特征是涉及8號和14號染色體的易位，即 t(8;14)(q24;q11)。該易位將8號染色體上的 MYC 致癌基因與14號染色體上的 T 細(xì)胞受體α鏈（TCR-alpha）基因緊密相連，導(dǎo)致 MYC 致癌基因的過表達，而 MYC 基因是已知的癌癥驅(qū)動基因。

  • 它表達關(guān)鍵的 T 細(xì)胞標(biāo)記物，如 CD2、CD3、CD5、CD7 和 T 細(xì)胞受體。

• 藥物敏感性: MOLT-16 細(xì)胞系已針對多種藥物的敏感性進行了分析，這些數(shù)據(jù)被用于藥物篩選項目。

研究應(yīng)用

MOLT-16 細(xì)胞系是腫瘤學(xué)研究，特別是兒童 T-ALL 研究的寶貴資源。其主要應(yīng)用包括：

• 疾病建模: 它作為 T 細(xì)胞急性淋巴細(xì)胞白血病的一個代表性模型，使研究人員能夠研究該疾病的進展和獨特的生物學(xué)特性。

• 遺傳和分子研究: 該細(xì)胞系被用于探究特定基因突變和易位（如 t(8;14) 易位）在 T-ALL 發(fā)生和維持中的作用。

• 藥物發(fā)現(xiàn)與篩選: 由于其已建立的遺傳和藥物反應(yīng)圖譜，它是篩選新療法和理解耐藥機制的關(guān)鍵工具

BioVector NTCC質(zhì)粒載體菌種細(xì)胞蛋白抗體基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947, 189-0126-8599

E-mail: [email protected]

http://www.nedfriskphoto.com